Malvern Panalytical Expands Pharmaceutical Drug Development Solutions Through Acquisition of Creoptix

Malvern Panalytical recently announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company. The acquisition forms a critical part of Malvern Panalytical’s strategy to expand its capabilities in support of drug discovery.

Creoptix provides cutting edge tools for molecular interaction analysis. Engineered around their proprietary Grating-Coupled Interferometry (GCI) technology, these tools enable researchers to access high-quality binding affinity and kinetics data across a broader range of samples than traditional SPR-based solutions, accelerating the discovery and development of new drug substances.

“We are really excited to be bringing the Creoptix team into the Malvern Panalytical family”, stated Mark Fleiner, President of Malvern Panalytical. “We have always been driven by our desire to support our customers in the development of ground-breaking new drug products. Creoptix significantly builds on the instrumentation and services capabilities we have to achieve this, strengthening our position in supporting small molecule pharmaceutical development while also significantly growing our capabilities in the fast-growing biopharmaceutical space.”

Engineered around their proprietary Grating-Coupled Interferometry (GCI) technology, these tools enable researchers to access high-quality binding affinity and kinetics data across a broader range of samples than traditional SPR-based solutions, accelerating the discovery and development of new drug substances.

Line Stigen Raquet, CEO Creoptix, also sees significant opportunities resulting from joining the Malvern Panalytical team. “The purpose of Creoptix has always been to enable life scientists to accelerate drug discovery”, said Line. “Our WAVE portfolio is designed with the vision to advance breakthrough science, and to help scientists develop new and better drugs, faster. We believe that this merger is an exciting opportunity to further accelerate and deliver on our purpose, as we benefit from the exceptional knowledge and global customer reach provided by Malvern Panalytical.”

Integration of Creoptix into the Malvern Panalytical family will start in January 2022 and is planned to be completed within the first half of 2022.

We draw on the power of our analytical instruments and services to make the invisible visible and the impossible possible. Through the chemical, physical and structural analysis of materials, our high-precision analytical systems and top-notch services support our customers in creating a better world, helping them to improve everything from the energies that power us and the materials we build with, to the medicines that cure us and the foods we enjoy. We partner with many of the world’s biggest companies, universities and research organizations. They value us not only for the power of our solutions, but also for the depth of our expertise, collaboration and integrity. With over 2200 employees, we serve the world, and we are part of Spectris plc, the world-leading precision measurement group. For more information, visit www.malvernpanalytical.com.

Creoptix is a company headquartered in Wädenswil, near Zurich, Switzerland, with a US office in the Boston area. Creoptix was founded in 2009 and has successfully gone through several financing rounds with Eduard Brunner from Start Angels Network, Privilège Ventures and Swisscanto (CH) Private Equity Switzerland Growth I Fund, respectively, as lead investors. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix WAVEsystem provides exceptionally high sensitivity and resolution to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics, and other molecules even in biofluids like undiluted serum or plasma. For more information, visit www.creoptix.com.